Search Within

Gynecologic Medicine Service

Formats
  1. Journal Article (1104)
  2. Meeting Abstract (902)
  3. Review (55)
  4. Book Section (46)
  5. Editorial (36)
  6. Guidelines (22)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Solid Tumor Oncology Division (2180)
  2. Department of Medicine (2174)
  3. Gynecology Disease Management Team (1877)
  4. GDMT, Medicine (1859)
  5. Surgery (603)
  6. GDMT, Surgery (479)

More Groups

People
  1. Carol Aghajanian (615)
  2. Nadeem Abu-Rustum (292)
  3. Martee Hensley (290)
  4. Roisin O'Cearbhaill (273)
  5. Vicky Makker (269)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (75)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (458)
  2. Gynecologic Oncology (420)
  3. International Journal of Gynecological Cancer (161)
  4. Annals of Oncology (117)
  5. Clinical Cancer Research (71)
  6. Cancer Research (55)

More Publications

Publishers
  1. American Society of Clinical Oncology (498)
  2. Elsevier B.V. (446)
  3. Lippincott Williams & Wilkins (188)
  4. American Association for Cancer Research (173)
  5. Oxford University Press (144)
  6. Elsevier Inc. (128)

More Publishers

Results (2180)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A first-in-human phase 1 study Of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors (trial in progress)
    Meeting Abstract

    Ray-Coquard, I. L.; O'Malley, D. M.; Oaknin, A.; Pothuri, B.; Lorusso, D.; Eskander, R. N.; Westin, S. N.; Lakhani, N.; McKean, W. B.; Koyama, T.; more...
    International Journal of Gynecological Cancer (2025)

    Fulltext@MSK | Save
  • An open-label, multicentre, phase 2 study of trastuzumab deruxtecan in patients with HER2-expressing solid tumours: DESTINY-PanTumor02 Part 2
    Meeting Abstract

    Oaknin, A.; Lee, J. Y.; Makker, V.; Oh, D. Y.; Anoka, C.; Jung, L.; Puvvada, S.; Simões, J.; Meric-Bernstam, F.
    International Journal of Gynecological Cancer (2025)

    Fulltext@MSK | Save
  • Multimodal AI modeling of clinical panel-based sequencing for HRD detection in ovarian cancer
    Meeting Abstract

    Alsaafin, A.; Pollard, T.; Aukerman, A. T.; Boehm, K.; Pasha, A.; Moore, D.; Rusk, N.; Begum, A.; Sullivan, M. W.; Graves, S.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers
    Meeting Abstract

    Fernandez, E. E.; Garralda, E.; Parikh, A.; Italiano, A.; Hollebecque, A.; Marabelle, A.; Friedman, C.; Sullivan, R.; Tschernia, N.; Juarez, M. M. H.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
    Journal Article

    Eskander, R. N.; Lee, J. Y.; Mirza, M. R.; Lorusso, D.; MacKay, H.; Ray-Coquard, I.; Oaknin, A.; Gonzalez-Martin, A.; Hasegawa, K.; Corr, B. R.; more...
    International Journal of Gynecological Cancer (2025)

    Fulltext@MSK | Save
  • Whole-genome sequencing-based characterization of endometrial serous carcinoma
    Journal Article

    Andres, S.; Brown, D. N.; da Cruz Paula, A.; Aghajanian, C.; Abu-Rustum, N. R.; Ellenson, L. H.; Weigelt, B.
    Gynecologic Oncology (2025)

    Fulltext@MSK | Save
  • Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?
    Journal Article

    Sia, T. Y.; Moufarrij, S.; Milani, J.; Kane, S.; Zhou, Q.; Fong, C.; Khurram, A.; Kemel, Y. M.; Sheehan, M.; Latham, A.; more...
    Gynecologic Oncology (2025)

    Fulltext@MSK | Save
  • Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1
    Meeting Abstract

    Friedman, C. F.; Sullivan, R. J.; Tschernia, N.; Sonpavde, G. P.; Herrera, M.; He, K.; Bilusic, M.; Garralda, E.; Hernando-Calvo, A. H.; Silk, A. W.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors
    Meeting Abstract

    O'Cearbhaill, R. E.; Barve, M. A.; Darus, C.; Gabrail, N. Y.; Johannet, P.; Loh, J.; Lerose, M.; Andreas, K.; Ullmann, C. D.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma
    Journal Article

    Liu, J. F.; Colombo, N.; Oza, A. M.; Frenel, J. S.; Corr, B. R.; Rubinstein, M. M.; Nevadunsky, N. S.; Lheureux, S.; Gaba, L.; González Cortijo, L.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save